Clinical Trial Update: Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating bevacizumab with an autologous tumor/dendritic cell vaccine plus interleukin-2 and interferon alfa-2b in metastatic renal cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Autologous tumor/dendritic cell vaccine
• Bevacizumab (Avastin) (bevacizumab)
• Interferon alfa-2b (Intron A) (interferon alfa-2b)
• Interleukin-2 (Aldesleukin) (aldesleukin)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2015-12-01